Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue S Ciavarella, MC Vegliante, M Fabbri, S De Summa, F Melle, G Motta, ... Annals of Oncology 29 (12), 2363-2370, 2018 | 116 | 2018 |
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue S Ciavarella, MC Vegliante, M Fabbri, S De Summa, F Melle, G Motta, ... Annals of Oncology, 2018 | 116 | 2018 |
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and … J Delgado, M Doubek, T Baumann, J Kotaskova, S Molica, P Mozas, ... American journal of hematology 92 (4), 375-380, 2017 | 116 | 2017 |
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma L Mansouri, D Noerenberg, E Young, E Mylonas, M Abdulla, M Frick, ... Blood 128 (23), 2666-2670, 2016 | 98 | 2016 |
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma JE Ramis-Zaldivar, B Gonzalez-Farré, O Balagué, V Celis, F Nadeu, ... Blood, The Journal of the American Society of Hematology 135 (4), 274-286, 2020 | 93 | 2020 |
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era A Rivas‐Delgado, L Magnano, M Moreno‐Velázquez, O Garcia, F Nadeu, ... British journal of haematology 184 (5), 753-759, 2019 | 79 | 2019 |
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia F Nadeu, R Royo, R Massoni-Badosa, H Playa-Albinyana, B Garcia-Torre, ... Nature medicine 28 (8), 1662-1671, 2022 | 78 | 2022 |
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions A Puiggros, R Collado, MJ Calasanz, M Ortega, N Ruiz-Xivillé, ... Oncotarget 8 (33), 54297, 2017 | 63 | 2017 |
Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study A Rivas-Delgado, F Nadeu, A Enjuanes, S Casanueva-Eliceiry, P Mozas, ... Clinical Cancer Research 27 (2), 513-521, 2021 | 56 | 2021 |
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome M Duran-Ferrer, G Clot, F Nadeu, R Beekman, T Baumann, J Nordlund, ... Nature Cancer 1 (11), 1066-1081, 2020 | 55 | 2020 |
High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and … I Dlouhy, X Filella, J Rovira, L Magnano, A Rivas-Delgado, T Baumann, ... Leukemia research 59, 20-25, 2017 | 53 | 2017 |
Clinical impact of a 6-week preoperative very low calorie diet on body weight and liver size in morbidly obese patients J González-Pérez, S Sánchez-Leenheer, AR Delgado, ... Obesity surgery 23, 1624-1631, 2013 | 53 | 2013 |
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma JG Valero, A Matas-Céspedes, F Arenas, V Rodriguez, J Carreras, ... Leukemia 35 (9), 2635-2649, 2021 | 46 | 2021 |
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population L Magnano, S Alonso‐Alvarez, M Alcoceba, A Rivas‐Delgado, ... British journal of haematology 185 (3), 480-491, 2019 | 36 | 2019 |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study A Cuneo, G Follows, GM Rigolin, A Piciocchi, A Tedeschi, L Trentin, ... haematologica 103 (7), 1209-1217, 2018 | 36 | 2018 |
IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms F Nadeu, R Mas-de-Les-Valls, A Navarro, R Royo, S Martín, N Villamor, ... Nature communications 11 (1), 3390, 2020 | 34 | 2020 |
PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax N Serrat, M Guerrero-Hernández, A Matas-Céspedes, A Yahiaoui, ... Blood advances 4 (17), 4217-4231, 2020 | 30 | 2020 |
Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma L Magnano, O Balagué, I Dlouhy, J Rovira, K Karube, M Pinyol, ... Annals of Oncology 28 (11), 2799-2805, 2017 | 28 | 2017 |
Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience P Mozas, F Nadeu, A Rivas-Delgado, A Rivero, M Garrote, O Balagué, ... Blood cancer journal 10 (3), 31, 2020 | 27 | 2020 |
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational … A Vidal-Crespo, V Rodriguez, A Matas-Cespedes, E Lee, ... Haematologica 102 (11), e447, 2017 | 20 | 2017 |